Oragenics Inc. Files 8-K Report

Ticker: OGEN · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1174940

Oragenics INC 8-K Filing Summary
FieldDetail
CompanyOragenics INC (OGEN)
Form Type8-K
Filed DateOct 9, 2024
Risk Levellow
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, exhibits

TL;DR

Oragenics filed an 8-K, mostly standard stuff, check exhibits for details.

AI Summary

On October 9, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicating a routine disclosure of corporate information rather than a specific material event. No new financial figures or significant business developments were detailed in the provided excerpt.

Why It Matters

This filing serves as a standard disclosure for Oragenics, Inc., providing updates on their financial statements and exhibits to the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, indicating no immediate material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Oragenics, Inc.?

The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of October 9, 2024.

What is Oragenics, Inc.'s state of incorporation and fiscal year end?

Oragenics, Inc. is incorporated in Florida (FL) and its fiscal year ends on December 31 (1231).

What is the filing date and the date of the earliest event reported?

The filing date and the date of the earliest event reported are both October 9, 2024.

What is the company's principal executive office address?

The company's principal executive office is located at 1990 Main Street, Suite 750, Sarasota, FL 34236.

What is Oragenics, Inc.'s telephone number?

Oragenics, Inc.'s telephone number is 813-286-7900.

Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-10-09 07:30:26

Filing Documents

SIGNATURES

SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 9 th day of October, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing